****OpenFold3 + NVIDIA BioNeMo/Roche/Insilico: open biomed + drug factories** [developing]
Key Questions
What is the Insilico Medicine deal with Lilly?
Insilico Medicine secured a $2.75B deal with Lilly following Phase 2 results. This partnership advances AI-driven drug discovery. It highlights the commercial success of AI in biomedicine.
What is OpenFold3?
OpenFold3 is an open-source tool tied to biomedicine and drug factories, enhancing protein structure prediction. It connects with HARVEST and InversePep for complex modeling. It supports scalable drug design workflows.
What role does NVIDIA BioNeMo play?
NVIDIA BioNeMo, in collaboration with Roche, Lilly, and Novo, generates 30M protein complexes. It powers open biomed platforms for drug discovery. Partnerships accelerate AI modeling in pharma.
What is UniDock-Pro?
UniDock-Pro is an integrated platform with GPU-accelerated UniDock for screening billions of compounds in hours. It advances molecular docking in drug discovery. It enables rapid virtual screening.
What are the current needs for these biomed AI systems?
Systems need improved benchmarks and wet-lab scaling for validation. While computational advances are strong, real-world testing lags. Development focuses on bridging these gaps.
Lilly $2.75B/Insilico deal post-Ph2; Proteina-Complexa/UniDock-Pro; BioNeMo/Roche/Lilly/Novo (30M complexes). Ties OpenFold3/HARVEST/InversePep. Needs benchmarks/wet-lab scaling.